awmsg logo



insulin glargine (Abasaglar®)


Reference No. 2307

Publication date:
10/12/2015


Appraisal information

insulin glargine (Abasaglar®) 100 units/ml solution for injection


Company: Eli Lilly & Co Ltd
BNF category: Endocrine system
NMG meeting date: 07/10/2015
AWMSG meeting date: 11/11/2015
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 3215
Ministerial ratification: 09/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Insulin glargine (Abasaglar®) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Insulin glargine (Abasaglar®) should be prescribed within its licensed indication in accordance with NICE or AWMSG guidance for insulin glargine (Lantus®), the reference product. Insulin glargine (Abasaglar®) is not recommended for use within NHS Wales outside of these circumstances. Insulin glargine (Abasaglar®) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download